Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COSTEM 2019 | Lenalidomide: should maintenance therapy after autograft be limited?

Sergio Giralt • 26 Oct 2019
COSTEM 2019
Multiple Myeloma Lenalidomide

Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, debates the utility, efficacy and limitation of maintenance therapy after autograft in multiple myeloma. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Sergio Giralt

The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
0:36
The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
Sergio Giralt • 16 Apr 2024
Overcoming barriers to treating older patients with myeloma
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
The potentially curative role of CAR-T therapy in myeloma
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
An update in cellular therapies: gene editing for SCD and immunotherapies for MM
1:12
An update in cellular therapies: gene editing for SCD and immunotherapies for MM
Sergio Giralt • 8 Dec 2023

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Sergio Giralt • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Sergio Giralt • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Sergio Giralt • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Sergio Giralt • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals